September 24, 2025Journal of Antimicrobial Chemotherapy
Possible increased risk of Epstein–Barr virus (EBV) infection and post-transplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients
Authors
Discussion
Loading...
Member takes
Implication
Observational analysis indicates higher rates of EBV infection and PTLD in recipients of haematopoietic cell transplantation exposed to letermovir, suggesting caution in management.
Key Points
- Increased risk of EBV infection and PTLD was observed in patients receiving letermovir, indicating a need for monitoring.
- The study analyzed the association between letermovir exposure and EBV-related complications in transplant recipients over time.
- Patients exposed to letermovir showed significantly elevated rates of PTLD, emphasizing the importance of careful post-transplant follow-up.
- Findings may influence clinical guidelines regarding the use of letermovir in haematopoietic cell transplantation.
Cite This Study
Camargo et al. (2025) studied this question.